Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hongdo Do

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Transplantation Direct|July 24, 2019
The Measurement of Donor-Specific Cell-Free DNA Identifies Recipients With Biopsy-Proven Acute Rejection Requiring Treatment After Liver TransplantationSu Kah Goh, Hongdo Do, Adam Testro, et al.
BMC Cancer|March 10, 2011
Integrated mutation, copy number and expression profiling in resectable non-small cell lung cancerGenni M Newnham, Matthew Conron, Sueanne McLachlan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 12, 2014
The clinical relevance of pathologic subtypes in metastatic lung adenocarcinomaTimothy D Clay, Hongdo Do, Vijaya Sundararajan, et al.
Pathology|December 5, 2013
EGFR gene copy number alterations are not a useful screening tool for predicting EGFR mutation status in lung adenocarcinomaPrudence A Russell, Yong Yu, Hongdo Do, et al.
Medical Oncology (Northwood, London, England)|September 8, 2017
EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinomaTimothy D Clay, Prudence A Russell, Hongdo Do, et al.
Asia-Pacific Journal of Clinical Oncology|March 1, 2014
Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLCMichael Michael, Shane C White, Ehtesham Abdi, et al.
Lung Cancer (Amsterdam, Netherlands)|June 17, 2020
NTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancerJose Luis Leal, Geoffrey Peters, Marcin Szaumkessel, et al.
Scientific Reports|April 16, 2013
A multisite blinded study for the detection of BRAF mutations in formalin-fixed, paraffin-embedded malignant melanomaAnna Richter, Fabienne Grieu, Amerigo Carrello, et al.
Clinical Epigenetics|April 11, 2015
Quantitative methodology is critical for assessing DNA methylation and impacts on correlation with patient outcomeAnnette M Lim, Ida Lm Candiloro, Nicholas Wong, et al.
International Journal of Cancer|January 18, 2014
Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcomeAnnette M Lim, Hongdo Do, Richard J Young, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Transplantation Direct|July 24, 2019
The Measurement of Donor-Specific Cell-Free DNA Identifies Recipients With Biopsy-Proven Acute Rejection Requiring Treatment After Liver TransplantationSu Kah Goh, Hongdo Do, Adam Testro, et al.
BMC Cancer|March 10, 2011
Integrated mutation, copy number and expression profiling in resectable non-small cell lung cancerGenni M Newnham, Matthew Conron, Sueanne McLachlan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 12, 2014
The clinical relevance of pathologic subtypes in metastatic lung adenocarcinomaTimothy D Clay, Hongdo Do, Vijaya Sundararajan, et al.
Pathology|December 5, 2013
EGFR gene copy number alterations are not a useful screening tool for predicting EGFR mutation status in lung adenocarcinomaPrudence A Russell, Yong Yu, Hongdo Do, et al.
Medical Oncology (Northwood, London, England)|September 8, 2017
EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinomaTimothy D Clay, Prudence A Russell, Hongdo Do, et al.
Asia-Pacific Journal of Clinical Oncology|March 1, 2014
Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLCMichael Michael, Shane C White, Ehtesham Abdi, et al.
Lung Cancer (Amsterdam, Netherlands)|June 17, 2020
NTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancerJose Luis Leal, Geoffrey Peters, Marcin Szaumkessel, et al.
Scientific Reports|April 16, 2013
A multisite blinded study for the detection of BRAF mutations in formalin-fixed, paraffin-embedded malignant melanomaAnna Richter, Fabienne Grieu, Amerigo Carrello, et al.
Clinical Epigenetics|April 11, 2015
Quantitative methodology is critical for assessing DNA methylation and impacts on correlation with patient outcomeAnnette M Lim, Ida Lm Candiloro, Nicholas Wong, et al.
International Journal of Cancer|January 18, 2014
Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcomeAnnette M Lim, Hongdo Do, Richard J Young, et al.
Pageof 5